Clinical trial
A Single-Center, Open-Label Case Study to Assess Scalp Serum Paired With HydraFacial HydraScalp Keravive™ Treatment in Patients With Self-Perceived Hair Thinning
NCT07935993 is registered in ClinicalTrials.gov with Revision Skincare as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-Center, Open-Label Case Study to Assess Scalp Serum Paired With HydraFacial HydraScalp Keravive™ Treatment in Patients With Self-Perceived Hair Thinning
- Lead sponsor
- Revision Skincare
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- November 9, 2026
- Completion date
- November 7, 2027
- Enrollment
- 15 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
hair loss, hair thinning
Arms
As registered; 1 arm.
-
Scalp Serum
Scalp Serum to be applied immediately after HydraScalp Treatment and once daily in the AM or PM on Wet or Dry hair.
Primary endpoints
Registered primary outcome measures; 3 primary.
-
Improvement in the appearance of thicker, fuller hair, as measured by clinical photography
Improvement in the appearance of thicker, fuller hair will be measured by Canfield HairMetrix® image analysis and clinical photography at Weeks 4, 8, and 12 compared to baseline, following three (3) HydraScalp Keravive™ treatments paired with once-daily use of the Sponsor's scalp serum. Clinical photography will be assessed for visual improvement in thicker, fuller hair. Canfield HairMetrix images will be analyzed for improvements in hair density, where an increase in score indicates improvement.
-
Improvement in hair and scalp attributes measured by subjects through a self-assessment questionnaire
Subjects will complete a self-assessment questionnaire to evaluate perceived improvement in hair and scalp attributes at Weeks 4, 8, and 12. Subjects will be asked to rate a series of statements on a 5 point scale: 1-completely disagree, 2-slightly disagree, 3- neither disagree or agree, 4- agree, and 5-completely agree. The best outcome is to Completely Agree with the statement / question being asked.
-
Improvement in subject quality of life measured by a questionnaire
Improvement in Quality of Life (QOL) questionnaire at Week 12 compared to baseline. Subjects will be asked to rate a series of statements on a 5 point scale: 1-completely disagree, 2-slightly disagree, 3- neither disagree or agree, 4- agree, and 5-completely agree. A shift from score 4 - 5 at baseline to score 1 - 3 at post baseline timepoints would indicate an improvement.
Lead sponsor's other trials
Revision Skincare, most recent start first.
+14 more trials See the organization page
Similar trials
Same condition (Alopecia) and phase, most recent start first.
+196 more trials See the condition page